What Do Hedge Funds Think of Novavax, Inc. (NVAX)?

Now, specific money managers were breaking ground themselves. Deerfield Management, managed by James E. Flynn, established the biggest position in Novavax, Inc. (NASDAQ:NVAX). Deerfield Management had $7.4 million invested in the company at the end of the quarter. Hal Mintz’s Sabby Capital also made a $3.7 million investment in the stock during the quarter. The following funds were also among the new NVAX investors: David Costen Haley’s HBK Investments, Chao Ku’s Nine Chapters Capital Management, and John Overdeck and David Siegel’s Two Sigma Advisors.

Let’s now review hedge fund activity in other stocks similar to Novavax, Inc. (NASDAQ:NVAX). We will take a look at The Ryland Group, Inc. (NYSE:RYL), Lexington Realty Trust (NYSE:LXP), GATX Corporation (NYSE:GMT), and Balchem Corporation (NASDAQ:BCPC). This group of stocks’ market valuations resemble NVAX’s market valuation.

As you can see these stocks had an average of 15.75 hedge funds with bullish positions and the average amount invested in these stocks was $225 million. That figure was $101 million in NVAX’s case. The Ryland Group, Inc. (NYSE:RYL) is the most popular stock in this table. On the other hand Balchem Corporation (NASDAQ:BCPC) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Novavax, Inc. (NASDAQ:NVAX) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.